NCT06690736 Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
| NCT ID | NCT06690736 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University |
| Condition | CXCR4-related Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-03-01 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Eligibility Criteria
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06690736 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying CXCR4-related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06690736 currently recruiting?
Yes, NCT06690736 is actively recruiting participants. Contact the research team at dreamadam@126.com for enrollment information.
Where is the NCT06690736 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06690736 clinical trial?
NCT06690736 is sponsored by Tianjin Medical University. The trial plans to enroll 200 participants.